14 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
that is inconsistent with the rights, licenses and assignments granted to the other Party in this Agreement.
7.2 No Debarment; Anti-Bribery and Anti-Corruption … and Anti-Corruption. Licensor and Licensee acknowledge and agree that there are anti-bribery and anti-corruption laws to which Licensor and Licensee
8-K
EX-10.2
qlc7 m5yq3qjia9fkb4e
16 Oct 18
Entry into a Material Definitive Agreement
8:57pm
425
EX-10.2
hbfkuxnu
16 Oct 18
Business combination disclosure
8:56pm
8-K
EX-1.1
w2wm7b5iox qmb3a
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-1.1
s2hz21b1p8lyw48g
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
- Prev
- 1
- Next